Treatment of immune disease by mucosal delivery of antigents using genetically modified Lactobacillus
AssigneeActogenix N.V.
InventorsPieter Rottiers, Veerle Snoeck
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular Lactococcus lactis, of secreted immunodominant antigens.
Claims15
A method of treating celiac disease in a subject comprising mucosally delivering a composition to the subject, wherein the composition comprises a genetically engineered Lactococcus lactis constitutively expressing and secreting an α-gliadin peptide or a hordein peptide, each peptide comprising a HLA-DQ2-specific epitope or a HLA-DQ8-specific epitope, wherein the composition is delivered mucosally to the subject at least once a day.
Dependencies are inferred from the claim text.